Compare Microsoft (MSFT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs ResMed Inc. — how do they compare? Microsoft trades at $526.69 (market cap $3.93T), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: Microsoft is far larger — about 123.7× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and ResMed Inc. for 51 Days on average.
| MSFT | RMD | |
|---|---|---|
Market Cap | $3.93T | $31.78B |
Volume | 16,040,951 | 1,128,382 |
Sector | Technology | Health |
52-Week High | $542.07 | $277.88 |
52-Week Low | $352.83 | $182.82 |
Typical Hold Time | 142 Days | 51 Days |
Enterprise Value | $3.91T | $31.14B |
Dividend Yield | 0.74% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $522.61, down 1.26% on the day, amid a bullish technical setup with strong moving average signals and key support at $522. The company reported robust fundamentals with Q2 2026 EPS of $4.74 beating estimates, revenue growth to $281.72B in 2025, and net income margins of 40.31%. Recent news highlights AI leadership and Azure momentum, though RSI levels suggest overbought conditions.
Outlook remains positive with an 81.71% analyst buy rating and a $571.76 consensus price target, implying ~9% upside. Risks include elevated capital expenditure concerns and competitive pressures in AI. Strong cash flow generation and a declining debt-to-asset ratio support long-term growth, but investors should monitor execution on AI investments and macroeconomic headwinds.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
